![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/eu-bulks-pre-pandemic-vaccine-stockpile-four-year-csl-seqirus-contract-40-million-bird-flu
https://www.prnewswire.com/news-releases/csl-seqirus-a-proud-champion-of-pandemic-preparedness-announces-us-government-award-in-response-to-avian-influenza-302159392.html
https://www.prnewswire.com/news-releases/recently-published-real-world-evidence-study-shows-effectiveness-of-cell-based-quadrivalent-influenza-vaccine-over-three-seasons-302134540.html
https://www.fiercepharma.com/manufacturing/uk-enlists-csl-seqirus-standby-flu-pandemic-preparedness-shots-produced-liverpool#:~:text=Tuesday%2C%20the%20UK%20Health%20Security,next%20four%20years%2C%20CSL%20said.
https://www.prnewswire.com/news-releases/seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-the-202223-us-season-301583651.html
https://www.prnewswire.com/news-releases/cdc-advisory-committee-includes-fluad-quadrivalent-as-a-preferentially-recommended-influenza-vaccine-for-adults-65-and-older-301573521.html
https://www.prnewswire.com/news-releases/seqirus-holly-springs-manufacturing-facility-designated-by-us-government-as-pandemic-ready-301560087.html
https://endpts.com/sanofi-petitions-fda-over-misleading-label-for-rival-flu-vaccine-that-failed-to-confirm-benefit/
https://www.prnewswire.com/news-releases/seqirus-and-us-government-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response-301490505.html
https://www.prnewswire.com/news-releases/seqirus-announces-us-fda-approval-for-multi-dose-vial-presentation-of-first-ever-adjuvanted-cell-based-pandemic-influenza-vaccine-301430826.html